Site is Being Upgraded

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA)   increases the expression of tumor/metastatic suppressors TPM1 and TAp63 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 14/February/2018, 11.20 pm

Combinatorial therapy for Myocardial Infarction:  A pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and D-3-Hydroxybutyrate  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 14/February/2018, 11.06 pm
February 14, 2018
Vitamin-based therapy for glucose homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Omeprazole increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 14/February/2018, 11.32 pm
February 14, 2018
Show all

From significance of the study to Public health relevance: 

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

This study suggests, for the first time, that  a pharmaceutical mixture(DHAASA) encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA), by regulating the expression of its target genes, it may increase the expression of tumor/metastatic suppressors TPM1 and TAp63 (fig. 1).

 

Thereby, it may: (a) inhibit cell cycle progression; and (b) suppress migration, invasion and metastasis of cancer cells.   [easy_payment currency=”USD”]

Given the mechanism of action of DHAASA , it may be an ideal anti-metastatic agent to  (i) increase the expression of metastasis suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy.

Taken together, this study suggests that oncologists may consider treating terminally ill metastatic cancer patients with Docosahexaenoic acid (DHA) and Aspirin (ASA) , as it may stall the progression of advanced metastatic cancers.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D

Amount: $5#

Undisclosed mechanistic information: How a pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA)  increases the expression of  tumor/metastatic suppressors TPM1 and TAp63 

Fig1. Mechanistic insights into how a therapeutic mix encompassing  Docosahexaenoic acid (DHA) and Aspirin (ASA) functions as an anti-metastasis agent. Docosahexaenoic acid (DHA) and Aspirin (ASA)  increase the expression of tumor/metastatic suppressors TPM1 and TAp63 via up regulation of their target genes

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

CitationBoominathan, L., Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA)   increases the expression of tumor/metastatic suppressors TPM1 and TAp63 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 14/February/2018, 11.20 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.